Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera [17]

Leukemia

Volumn 21, Issue 9, 2007, Pages 2074-2075

  Tefferi, A ^a   Strand, J J ^a   Lasho, T L ^a   Knudson, R A ^a   Finke, C M ^a   Gangat, N ^a   Pardanani, A ^a   Hanson, C A ^a   Ketterling, R P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; HEMOGLOBIN; JANUS KINASE 2; JANUS KINASE 2 V617F; MESSENGER RNA; UNCLASSIFIED DRUG;

ALLELE; ARTERY THROMBOSIS; BONE MARROW; CONTROLLED STUDY; CORRELATION ANALYSIS; FATALITY; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; LETTER; LEUKEMIA; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; MYELOFIBROSIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; SYMPTOMATOLOGY; THROMBOCYTE COUNT; VEIN THROMBOSIS;

EID: 34548131123     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404724     Document Type: Letter

References (7)

1. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468.
2. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006; 106: 631-635.
3. Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 2006; 20: 1055-1060.
4. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139-4141.
5. Gale RE, Allen AJ, Nash MJ, Linch DC. Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. Blood 2007; 109: 1241-1243.
6. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP et al. Clinical Correlates of JAK2V617F Allele Burden in Essential Thrombocythemia. Cancer 2007; in press.
7. Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: A single institutional study of 605 patients. Leukemia 2007; 21: 270-276.